Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

BACKGROUND: Monotherapy with immune checkpoint blockade is ineffective for patients (pts) with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). This study investigates whether the combination of trametinib (T) with durvalumab (D) can alter the immune tumor microenvironment (TME) by s...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Benny, Haymaker, Cara L, Parra, Edwin R, Soto, Luisa Maren Solis, Wang, Xuemei, Thomas, Jane V, Dasari, Arvind, Morris, Van K, Raghav, Kanwal, Vilar, Eduardo, Kee, Bryan K, Eng, Cathy, Parseghian, Christine M, Wolff, Robert A, Lee, Younghee, Lorenzini, Daniele, Laberiano-Fernandez, Caddie, Verma, Anuj, Lang, Wenhua, Wistuba, Ignacio I, Futreal, Andrew, Kopetz, Scott, Overman, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422817/
https://www.ncbi.nlm.nih.gov/pubmed/36007963
http://dx.doi.org/10.1136/jitc-2022-005332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422817/
https://www.ncbi.nlm.nih.gov/pubmed/36007963
http://dx.doi.org/10.1136/jitc-2022-005332

Ejemplares similares